Deciphering Atopic Dermatitis Therapy Options
Dermatology Times
JUNE 2, 2024
James Song, MD, addressed current challenges in the AD treatment landscape and compared biologics.
This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Dermatology Times
JUNE 2, 2024
James Song, MD, addressed current challenges in the AD treatment landscape and compared biologics.
The Dermatology Digest
APRIL 7, 2024
A newly developed therapeutic ladder can help guide dermatologists and patients on the use of nonsteroidal treatment options for atopic dermatitis (AD). Nonsteroidal treatment options for AD have rapidly expanded in recent years with the development of phosphodiesterase-4 inhibitors, biologics, and Janus kinase (JAK) inhibitors.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Dermatology Times
OCTOBER 5, 2023
Colleen Cotton, MD, discusses the treatment landscape of pediatric atopic dermatitis, highlights from her session at Maui Derm NP+PA in Asheville, NC, and more.
Dermatology Times
OCTOBER 27, 2024
At Fall Clinical 2024, Christopher Bunick, MD, PhD, discussed systemic therapy options and the importance of comprehensive treatment targets in managing atopic dermatitis, emphasizing AHEAD recommendations and LEVEL UP data.
Dermatology Times
AUGUST 27, 2024
The AHEAD recommendations focus on achieving disease control in atopic dermatitis by allowing patients to identify key symptoms and clinicians to select matching outcomes to guide therapy, aiming for a higher standard of care.
First Derm
FEBRUARY 21, 2024
Treatment Approaches Vary : Treatment for eczema includes emollients and topical steroids, while psoriasis may be treated with light therapy, systemic medications, and biologics, emphasizing the need for personalized care. Contact dermatitis from metals, latex, chemicals. 2] Why is Eczema Considered a Chronic Condition?
Dermatology Times
DECEMBER 4, 2024
Gina Mangin, MPAS, PA-C, discusses how developing an effective atopic dermatitis treatment plan requires a personalized, multifaceted approach that combines proper skin care, trigger avoidance, topical medications, and potentially systemic therapies based on the severity of symptoms and individual patient needs.
First Derm
JUNE 10, 2024
Online Dermatologist Atopic Dermatitis vs. Contact Dermatitis: What’s the Difference? Atopic dermatitis (left) and contact dermatitis (right) display different symptoms. Contact Dermatitis : Triggered by external irritants or allergens, causing localized redness, blisters, and itching.
Dermatology Times
MAY 30, 2024
Lawrence Eichenfield, MD, discusses the numerous limitations of current topical treatments for atopic dermatitis (AD), their impact on patient management, adherence, and quality of life, the common obstacles patients face in achieving adequate disease control with these therapies, and compares ruxolitinib cream as a nonsteroidal monotherapy alternative. (..)
Dermatology Times
AUGUST 9, 2024
Explore how surveyed providers perceive current and emerging therapies in the atopic dermatitis.
Dermatology Times
DECEMBER 10, 2024
Panelists discuss how managing atopic dermatitis presents complex clinical challenges, including treatment resistance, medication adherence, identifying triggers, and tailoring therapies to individual patient needs and disease severity.
The Dermatology Digest
DECEMBER 11, 2024
SYM2081 inhibits inflammation-driving mast cells in mouse models and human skin samples, paving the way for new topical treatments to prevent itching, hives, and other symptoms of skin conditions driven by mast cells, finds a study published in Science Translational Medicine.
Dermatology Times
JUNE 2, 2024
James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.
First Derm
FEBRUARY 6, 2024
Online Dermatologist Topical Steroid Withdrawal: Causes, Symptoms, and Treatments What is Topical Steroid Withdrawal? Professional Guidance is Essential : Consulting healthcare professionals is vital for obtaining an accurate diagnosis, understanding your condition, and developing a personalized treatment plan. Dermatitis.
The Dermatology Digest
FEBRUARY 14, 2024
Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). Galderma is planning for multiple regulatory submissions in 2024.
Dermatology Times
JUNE 20, 2024
Lawrence Eichenfield, MD, explores the significant comorbidities and conditions, such as allergic rhinitis, anxiety, and asthma, that intersect with atopic dermatitis (AD), discussing their influence on disease management and treatment response, as well as the observed treatment patterns of patients with this condition before and after the initiation (..)
First Derm
DECEMBER 4, 2023
Dry skin is a very common problem in people with atopic dermatitis, a chronic inflammatory skin condition characterized by patches of itchy, dry, red, and inflamed skin. Atopic dermatitis (eczema) characterized by itchy patches of red, inflamed, dry skin. Therapeutic implications of a barrier-based pathogenesis of atopic dermatitis.
The Dermatology Digest
FEBRUARY 8, 2024
Psoriasis is also undergoing a revolution with the development of new oral treatments that act like injectable biologics, and this is of interest to patients who do not want a shot,” he says. This will be a game-changer if it pans out and may get us closer to disease cures via optimization of existing biological therapies,” he says.
Dermatology Times
MARCH 29, 2024
Brian Kim, MD, explores long-term ruxolitinib data and combination therapies in the treatment of pediatric atopic dermatitis.
Dermatology Times
DECEMBER 3, 2024
Promising new data was released along with a timeline of upcoming studies evaluating potential combination therapies for atopic dermatitis.
Dermatology Times
SEPTEMBER 20, 2023
Audrey Dean discusses with her dermatologist, Jennifer Holman, MD, FAAD, how supportive therapies and dietary changes have altered her disease severity. Jennifer Holman goes on to highlight a wholistic approach to treatment, and how treating atopic dermatitis can have a multidisciplinary approach.
First Derm
APRIL 5, 2024
Factors affecting adherence include socioeconomic status, treatment complexity, and the specific skin condition being treated. Strategies to improve adherence range from using eHealth tools and educational resources to simplifying treatment regimens.
US Dermatologt Partners
NOVEMBER 25, 2023
Atopic dermatitis (AD) is a multifaceted condition that can significantly impact a patient’s quality of life. I think that dermatitis started showing up once my psoriasis started showing up,” Dean said. “As As a physician, I have to do a better job intervening here [and] switch our systemic therapies.”
The Dermatology Digest
MARCH 11, 2024
Adding narrowband ultraviolet B phototherapy to treatment with ritlecitinib (Litfulo, Pfizer) in vitiligo may improve patient outcomes. Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Watch Now The Lowdown on Molluscum Nanette B.
US Dermatologt Partners
AUGUST 23, 2023
Atopic Dermatitis, more commonly known as eczema, is a common skin condition impacting one in 10 Americans. From identifying triggers and creating a customized daily skincare plan to discussing medications and other treatments, a dermatologist can help you achieve and maintain healthy skin.” Millions of people in the U.S.
The Dermatology Digest
MAY 2, 2024
Aslan and Zenyaku are teaming up to explore how eblasakimab’s mechanism of action differs from that of other biologic therapies for atopic dermatitis (AD). This new agreement expands upon the commercial agreement that Aslan signed with Zenyaku in June 2023 for the development and commercialization of eblasakimab in Japan.
Lipgloss and Aftershave
NOVEMBER 15, 2023
Role Of Hydration In Acne Treatment Not only is hydration key to plump, dewy, glowing, youthful skin, it should also be regarded as an acne treatment in its own right. DermaJEM Perfect Advanced Treatment Room Companion Using the DermaJEM Aria in your treatment room, you’ll be able to calm, cool, and soothe skin with the Cold Therapy.
First Derm
MARCH 22, 2024
Eczema herpeticum Medically reviewed by The Dermatologists and written by Dr. Alexander Börve In A Nutshell What It Is : Skin infection marked by fever and clusters of itchy blisters, often complicating atopic dermatitis. Who’s at Risk : Affects both genders and all ages, but more common in infants and children with atopic dermatitis.
Dermatology Times
APRIL 1, 2024
Brad Glick, DO, MPH, says it is essential to consider patient lifestyles when choosing atopic dermatitis therapies.
First Derm
JUNE 23, 2024
1] Three main categories of eczema are atopic eczema, contact dermatitis and stasis dermatitis. Eczema severity varies from person to person, so the treatment should be tailored to individual needs. While one product used in treatment may suit one individual, it might cause severe reactions in another.
The Dermatology Digest
OCTOBER 26, 2024
Atopic dermatitis (AD) patients who switched to upadacitinib (Rinvoq, AbbVie) from dupilumab (Dupixent, Regeneron, and Sanofi) hit higher treatment targets, according to results from Period 2 of the LEVEL UP study. Both groups had similar proportions of patients with treatment-emergent adverse events (TEAEs).
Dermatology Times
JULY 1, 2024
James Song, MD, shares a comprehensive guide to what is new, what is now, and what is next in AD treatment.
The Dermatology Digest
MARCH 13, 2024
Adam Friedman, MD, Professor and Chair of Dermatology at George Washington School of Medicine and Health Sciences in Washington, DC, shares his excitement about chronic spontaneous urticaria (CSU) treatments coming down the pike including remibrutinib, Novartis’ investigational oral Bruton’s tyrosine kinase inhibitor.
The Dermatology Digest
MARCH 10, 2024
Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC, discusses the need for a comprehensive treatment approach for CHE.
The Dermatology Digest
MARCH 10, 2024
Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC, discusses the need for a comprehensive treatment approach for CHE.
The Dermatology Digest
DECEMBER 13, 2024
Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) for the treatment of patients aged 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies.
Dermatology Times
AUGUST 12, 2024
This week’s collection of the latest dermatologic studies includes the impact of isotretinoin treatment on femoral cartilage thickness, cystic fibrosis dermatitis arthritis syndrome, the role of intratumoral therapies for cutaneous melanoma, and fractional pigment toning for treating benign epidermal pigmented lesions.
US Dermatologt Partners
SEPTEMBER 23, 2024
It’s important to develop healthy skin habits to slow the signs of aging around the eyes, and there are also dermatologic treatment options available when you need to hit the reset button.” Chronic skin conditions – poorly managed chronic skin conditions like eczema and dermatitis may damage or dilate blood vessels around the eyes.
The Dermatology Digest
JUNE 12, 2024
A human, monoclonal antibody targeting the interleukin (IL)-13 cytokine, tralokinumab is currently indicated in patients 12 and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Dermatology Times
JUNE 3, 2024
Kristine Kucera, PA-C, MPAS, DHS, and Mickey Bryson discuss Mickey's atopic dermatitis diagnostic process and the ineffective initial treatments, which included topical therapies, homeopathic remedies, and prednisone steroids.
The Dermatology Digest
DECEMBER 14, 2024
Food and Drug Administration approved two new therapies for atopic dermatitis (AD): Nemolizumab (Nemluvio, Galderma) and tapinarof cream, 1% (Vtama, Organon). In one day, treatment for moderate to severe AD was vastly improved. By Ted Rosen, MD Late Friday on December 13, 2024, the U.S.
First Derm
JULY 2, 2024
Online Dermatologist Sweating and Eczema: How to Manage Flare-Ups Eczema and Sweat | Symptoms of eczema | Physiology | How Sweating Affects Eczema | Triggers for Eczema | Related conditions | Managing Sweat to Prevent Eczema Flare-Ups | Treatment Key Takeaways Eczema, particularly atopic dermatitis, flares up with triggers like sweat.
The Dermatology Digest
JUNE 14, 2024
The late-breaking data, presented at the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois, showed that upadacitinib bested dupilumab for all ranked secondary endpoints of LEVEL-UP, including complete skin clearance and rapid resolution of itching in patients with severe itch.
American Esthetician Organization
AUGUST 21, 2023
Understanding the triggering factors can provide valuable insights into finding the most suitable treatment. Therefore, seeking appropriate treatment and management strategies is crucial for both physical and emotional well-being. What is Facial Redness? Facial redness is a common skin condition that affects many individuals.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content